Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Hepatopulmonary syndrome in adults: Natural history, treatment, and outcomes

Paul A Lange, MD
James K Stoller, MD, MS
Section Editor
Jess Mandel, MD
Deputy Editor
Geraldine Finlay, MD


Hepatopulmonary syndrome (HPS) is characterized by the triad of abnormal arterial oxygenation caused by intrapulmonary vascular dilatations (IPVD) in the setting of liver disease, portal hypertension, or congenital portosystemic shunts [1,2].

The natural history, treatment, and outcomes of HPS are reviewed here. The epidemiology, pathophysiology, clinical manifestations, and diagnostic evaluation are discussed separately. (See "Hepatopulmonary syndrome in adults: Prevalence, causes, clinical manifestations, and diagnosis".)


HPS is typically a progressive disorder, the presence of which worsens the prognosis of patients with cirrhosis and probably other liver diseases [1,3-7]. The cause of death among patients with HPS tends to be multifactorial and related to complications of underlying liver disease (eg, hepatic failure, multisystem organ failure due to sepsis, hepatocellular cancer, gastrointestinal bleeding) rather than from HPS-related hypoxemic respiratory failure [1,3,4]. Spontaneous resolution of HPS without treatment is unlikely. These conclusions are derived from the following studies:

One observational study of 138 liver transplant candidates reported a higher mortality in patients with HPS compared with case-matched controls (78 versus 43 percent) [4]. Similarly, patients with HPS had a lower median survival (24 versus 87 months) and lower five-year survival (23 versus 63 percent).

A single center prospective study of 316 patients referred for liver transplantation reported that compared with patients without HPS, patients with HPS had a nonsignificant increase in waitlist mortality (24 versus 16 percent) and a slightly lower pre-liver transplant survival (35 versus 42 months) [5].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Sep 19, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Rodríguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome--a liver-induced lung vascular disorder. N Engl J Med 2008; 358:2378.
  2. Krowka MJ, Fallon MB, Kawut SM, et al. International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation 2016; 100:1440.
  3. Schenk P, Schöniger-Hekele M, Fuhrmann V, et al. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 2003; 125:1042.
  4. Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology 2005; 41:1122.
  5. Pascasio JM, Grilo I, López-Pardo FJ, et al. Prevalence and severity of hepatopulmonary syndrome and its influence on survival in cirrhotic patients evaluated for liver transplantation. Am J Transplant 2014; 14:1391.
  6. Krowka MJ, Dickson ER, Cortese DA. Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue. Chest 1993; 104:515.
  7. Fallon MB, Krowka MJ, Brown RS, et al. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology 2008; 135:1168.
  8. Rodríguez-Roisin R, Krowka MJ, Hervé P, et al. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J 2004; 24:861.
  9. Tzovaras N, Stefos A, Georgiadou SP, et al. Reversion of severe hepatopulmonary syndrome in a non cirrhotic patient after corticosteroid treatment for granulomatous hepatitis: a case report and review of the literature. World J Gastroenterol 2006; 12:336.
  10. Arguedas MR, Abrams GA, Krowka MJ, Fallon MB. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 2003; 37:192.
  11. Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004; 10:174.
  12. Gupta S, Castel H, Rao RV, et al. Improved survival after liver transplantation in patients with hepatopulmonary syndrome. Am J Transplant 2010; 10:354.
  13. Schiffer E, Majno P, Mentha G, et al. Hepatopulmonary syndrome increases the postoperative mortality rate following liver transplantation: a prospective study in 90 patients. Am J Transplant 2006; 6:1430.
  14. Stoller JK, Lange PA, Westveer MK, et al. Prevalence and reversibility of the hepatopulmonary syndrome after liver transplantation. The Cleveland Clinic experience. West J Med 1995; 163:133.
  15. Collisson EA, Nourmand H, Fraiman MH, et al. Retrospective analysis of the results of liver transplantation for adults with severe hepatopulmonary syndrome. Liver Transpl 2002; 8:925.
  16. Taillé C, Cadranel J, Bellocq A, et al. Liver transplantation for hepatopulmonary syndrome: a ten-year experience in Paris, France. Transplantation 2003; 75:1482.
  17. Starzl TE, Groth CG, Brettschneider L, et al. Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery 1968; 63:549.
  18. Stoller JK, Moodie D, Schiavone WA, et al. Reduction of intrapulmonary shunt and resolution of digital clubbing associated with primary biliary cirrhosis after liver transplantation. Hepatology 1990; 11:54.
  19. Eriksson LS, Söderman C, Ericzon BG, et al. Normalization of ventilation/perfusion relationships after liver transplantation in patients with decompensated cirrhosis: evidence for a hepatopulmonary syndrome. Hepatology 1990; 12:1350.
  20. Barry S, Pingleton S, Kindscher J, et al. Comparison of shunt fractions pre- and post-liver transplantation. Transplant Proc 1993; 25:1801.
  21. Battaglia SE, Pretto JJ, Irving LB, et al. Resolution of gas exchange abnormalities and intrapulmonary shunting following liver transplantation. Hepatology 1997; 25:1228.
  22. Deberaldini M, Arcanjo AB, Melo E, et al. Hepatopulmonary syndrome: morbidity and survival after liver transplantation. Transplant Proc 2008; 40:3512.
  23. Iyer VN, Swanson KL, Cartin-Ceba R, et al. Hepatopulmonary syndrome: favorable outcomes in the MELD exception era. Hepatology 2013; 57:2427.
  24. Goldberg DS, Krok K, Batra S, et al. Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database. Gastroenterology 2014; 146:1256.
  25. Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014; 59:1144.
  26. Fallon MB, Mulligan DC, Gish RG, Krowka MJ. Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome. Liver Transpl 2006; 12:S105.
  27. Saigal S, Choudhary N, Saraf N, et al. Excellent outcome of living donor liver transplantation in patients with hepatopulmonary syndrome: a single centre experience. Clin Transplant 2013; 27:530.
  28. Carey EJ, Douglas DD, Balan V, et al. Hepatopulmonary syndrome after living donor liver transplantation and deceased donor liver transplantation: a single-center experience. Liver Transpl 2004; 10:529.
  29. Irei T, Onoe T, Das LK, et al. Successful resolution of very severe hepatopulmonary syndrome following adult-to-adult living donor liver transplantation: Report of two cases. Hepatol Res 2014.
  30. Stanley NN, Williams AJ, Dewar CA, et al. Hypoxia and hydrothoraces in a case of liver cirrhosis: correlation of physiological, radiographic, scintigraphic, and pathological findings. Thorax 1977; 32:457.
  31. Martinez G, Barberà JA, Navasa M, et al. Hepatopulmonary syndrome associated with cardiorespiratory disease. J Hepatol 1999; 30:882.
  32. Krowka MJ, Wiesner RH, Heimbach JK. Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward. J Hepatol 2013; 59:367.
  33. Van Thiel DH, Schade RR, Gavaler JS, et al. Medical aspects of liver transplantation. Hepatology 1984; 4:79S.
  34. Martínez-Palli G, Gómez FP, Barberà JA, et al. Sustained low diffusing capacity in hepatopulmonary syndrome after liver transplantation. World J Gastroenterol 2006; 12:5878.
  35. Schwarzenberg SJ, Freese DK, Regelmann WE, et al. Resolution of severe intrapulmonary shunting after liver transplantation. Chest 1993; 103:1271.
  36. Lange PA, Stoller JK. The hepatopulmonary syndrome. Effect of liver transplantation. Clin Chest Med 1996; 17:115.
  37. Al-Hussaini A, Taylor RM, Samyn M, et al. Long-term outcome and management of hepatopulmonary syndrome in children. Pediatr Transplant 2010; 14:276.
  38. Rodriguez-Roisin R, Krowka MJ. Is severe arterial hypoxaemia due to hepatic disease an indication for liver transplantation? A new therapeutic approach. Eur Respir J 1994; 7:839.
  39. Fallon MB. Hepatopulmonary syndrome: more than just a matter of tone? Hepatology 2006; 43:912.
  40. Aucejo F, Miller C, Vogt D, et al. Pulmonary hypertension after liver transplantation in patients with antecedent hepatopulmonary syndrome: a report of 2 cases and review of the literature. Liver Transpl 2006; 12:1278.
  41. Koch DG, Caplan M, Reuben A. Pulmonary hypertension after liver transplantation: case presentation and review of the literature. Liver Transpl 2009; 15:407.
  42. Nayyar D, Man HS, Granton J, et al. Proposed management algorithm for severe hypoxemia after liver transplantation in the hepatopulmonary syndrome. Am J Transplant 2015; 15:903.
  43. Nayyar D, Man HS, Granton J, Gupta S. Defining and characterizing severe hypoxemia after liver transplantation in hepatopulmonary syndrome. Liver Transpl 2014; 20:182.
  44. Meyers C, Low L, Kaufman L, et al. Trendelenburg positioning and continuous lateral rotation improve oxygenation in hepatopulmonary syndrome after liver transplantation. Liver Transpl Surg 1998; 4:510.
  45. Karnatovskaia LV, Matharu J, Burger C, Keller CA. Inhaled nitric oxide as a potential rescue therapy for persistent hepatopulmonary syndrome after liver transplantation. Transplantation 2014; 98:e64.
  46. Roma J, Balbi E, Pacheco-Moreira L, et al. Methylene blue used as a bridge to liver transplantation postoperative recovery: a case report. Transplant Proc 2010; 42:601.
  47. Lee HW, Suh KS, Kim J, et al. Pulmonary artery embolotherapy in a patient with type I hepatopulmonary syndrome after liver transplantation. Korean J Radiol 2010; 11:485.
  48. Auzinger G, Willars C, Loveridge R, et al. Extracorporeal membrane oxygenation for refractory hypoxemia after liver transplantation in severe hepatopulmonary syndrome: a solution with pitfalls. Liver Transpl 2014; 20:1141.
  49. O'Leary JG, Rees CR, Klintmalm GB, Davis GL. Inferior vena cava stent resolves hepatopulmonary syndrome in an adult with a spontaneous inferior vena cava-portal vein shunt. Liver Transpl 2009; 15:1897.
  50. Sahu MK, Bisoi AK, Chander NC, et al. Abernethy syndrome, a rare cause of hypoxemia: A case report. Ann Pediatr Cardiol 2015; 8:64.
  51. Chevallier P, Novelli L, Motamedi JP, et al. Hepatopulmonary syndrome successfully treated with transjugular intrahepatic portosystemic shunt: a three-year follow-up. J Vasc Interv Radiol 2004; 15:647.
  52. Paramesh AS, Husain SZ, Shneider B, et al. Improvement of hepatopulmonary syndrome after transjugular intrahepatic portasystemic shunting: case report and review of literature. Pediatr Transplant 2003; 7:157.
  53. Lasch HM, Fried MW, Zacks SL, et al. Use of transjugular intrahepatic portosystemic shunt as a bridge to liver transplantation in a patient with severe hepatopulmonary syndrome. Liver Transpl 2001; 7:147.
  54. Selim KM, Akriviadis EA, Zuckerman E, et al. Transjugular intrahepatic portosystemic shunt: a successful treatment for hepatopulmonary syndrome. Am J Gastroenterol 1998; 93:455.
  55. Benítez C, Arrese M, Jorquera J, et al. Successful treatment of severe hepatopulmonary syndrome with a sequential use of TIPS placement and liver transplantation. Ann Hepatol 2009; 8:71.
  56. Nistal MW, Pace A, Klose H, et al. Hepatopulmonary syndrome caused by sarcoidosis of the liver treated with transjugular intrahepatic portosystemic shunt. Thorax 2013; 68:889.
  57. Tsauo J, Weng N, Ma H, et al. Role of Transjugular Intrahepatic Portosystemic Shunts in the Management of Hepatopulmonary Syndrome: A Systemic Literature Review. J Vasc Interv Radiol 2015; 26:1266.
  58. Martinez-Palli G, Drake BB, Garcia-Pagan JC, et al. Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome. World J Gastroenterol 2005; 11:6858.
  59. Saad NE, Lee DE, Waldman DL, Saad WE. Pulmonary arterial coil embolization for the management of persistent type I hepatopulmonary syndrome after liver transplantation. J Vasc Interv Radiol 2007; 18:1576.
  60. Grady K, Gowda S, Kingah P, Soubani AO. Coil embolization of pulmonary arteries as a palliative treatment of diffuse type I hepatopulmonary syndrome. Respir Care 2015; 60:e20.
  61. De BK, Dutta D, Pal SK, et al. The role of garlic in hepatopulmonary syndrome: a randomized controlled trial. Can J Gastroenterol 2010; 24:183.
  62. Tieppo J, Cuevas MJ, Vercelino R, et al. Quercetin administration ameliorates pulmonary complications of cirrhosis in rats. J Nutr 2009; 139:1339.
  63. Sztrymf B, Rabiller A, Nunes H, et al. Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J 2004; 23:752.
  64. Tanikella R, Philips GM, Faulk DK, et al. Pilot study of pentoxifylline in hepatopulmonary syndrome. Liver Transpl 2008; 14:1199.
  65. Gupta LB, Kumar A, Jaiswal AK, et al. Pentoxifylline therapy for hepatopulmonary syndrome: a pilot study. Arch Intern Med 2008; 168:1820.
  66. Kianifar HR, Khalesi M, Mahmoodi E, Afzal Aghaei M. Pentoxifylline in hepatopulmonary syndrome. World J Gastroenterol 2012; 18:4912.
  67. Schenk P, Madl C, Rezaie-Majd S, et al. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med 2000; 133:701.
  68. Castro M, Krowka MJ. Hepatopulmonary syndrome. A pulmonary vascular complication of liver disease. Clin Chest Med 1996; 17:35.
  69. Fallon MB, Abrams GA. Pulmonary dysfunction in chronic liver disease. Hepatology 2000; 32:859.
  70. Brussino L, Bucca C, Morello M, et al. Effect on dyspnoea and hypoxaemia of inhaled N(G)-nitro-L-arginine methyl ester in hepatopulmonary syndrome. Lancet 2003; 362:43.
  71. Almeida JA, Riordan SM, Liu J, et al. Deleterious effect of nitric oxide inhibition in chronic hepatopulmonary syndrome. Eur J Gastroenterol Hepatol 2007; 19:341.
  72. Song JY, Choi JY, Ko JT, et al. Long-term aspirin therapy for hepatopulmonary syndrome. Pediatrics 1996; 97:917.
  73. Moreira Silva H, Reis G, Guedes M, et al. A case of hepatopulmonary syndrome solved by mycophenolate mofetil (an inhibitor of angiogenesis and nitric oxide production). J Hepatol 2013; 58:630.